Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New study to test antifungal drug safety in organ transplant patients

NCT ID NCT07656493

Knowledge-focused Sponsor: Sichuan Provincial People's Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study will observe 120 solid organ transplant recipients who have invasive fungal infections. Researchers will track how well the drug liposomal amphotericin B works and its side effects, compared to historical patients who received other antifungal treatments. The goal is to gather real-world evidence to guide better dosing and monitoring in this high-risk group.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Liposomal amphotericin B (an antifungal drug)
What this could lead to
If successful, this study could provide real-world data to help doctors better treat fungal infections in transplant patients, potentially improving survival and reducing side effects.
What could go wrong
This is an observational study, not a controlled trial, so results may be influenced by other factors. It is also small (120 participants) and single-center, limiting how widely findings can be applied.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 120 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jul 2026

An estimate. Start dates often move.

Expected to finish

Jun 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adult solid organ transplant recipients diagnosed with proven, probable, or possible invasive fungal disease and treated with liposomal amphotericin B or alternative systemic antifungal therapy at Sichuan Provincial People's Hospital.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 18 to 75 years. * Recipient of a solid organ transplant. * Diagnosis of invasive fungal disease (IFD) according to EORTC/MSGERC criteria. * Receiving liposomal amphotericin B therapy as part of routine clinical care. * Provision of informed consent for prospective participants. Exclusion Criteria: * Known hypersensitivity to amphotericin B formulations. * Severe hepatic dysfunction (ALT or AST \>5× upper limit of normal, or total bilirubin \>2× upper limit of normal). * Severe renal dysfunction requiring permanent discontinuation of antifungal therapy at baseline. * Pregnancy or breastfeeding. * Participation judged inappropriate by the investigator.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Invasive fungal infection are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Invasive Fungal Infections Opportunistic Infections opportunistic infectious systemic mycosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Invasive fungal infection Opportunistic infections Solid organ transplantation

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Sichuan Academy of Medical Sciences and Sichuan Provincial People's Hospital

    Chengdu, Sichuan, 610072, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.